Harmony Biosciences preannounced record quarterly net product revenue for WAKIX of approximately $261 million for the second quarter of 2026, representing 30% year-over-year growth and 21% sequential growth from the first quarter. The company reaffirmed its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion, citing strong demand and disciplined commercial execution. Harmony also announced that Chief Financial Officer Glenn Reicin has stepped down effective July 16, 2026, and that Stephen Mollichella, Senior Vice President and Controller, has been appointed Interim Principal Financial Officer. The company stated that Mr. Reicin's departure is not due to any disagreement and does not expect the transition to affect its performance. Full second-quarter 2026 financial results will be reported on August 4, 2026.
Harmony Biosciences HoldingsRecord Q2 revenue of $261M, 30% YoY growth, driven by strong demand for WAKIX.